EXEL

Exelixis, Inc. (EXEL) - Q1 2003 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2003. Exelixis, Inc. is a biotechnology company focused on developing proprietary human therapeutics, primarily in cancer, using an integrated discovery platform involving comparative genomics and model system genetics. The company relies heavily on collaborations with major pharmaceutical and agrochemical companies for revenue.

Key Financial Metrics

Liquidity: As of March 31, 2003, the company held approximately $203.9 million in cash, cash equivalents, short-term investments, and restricted cash. Management believes these resources are sufficient to fund operations for at least the next two years.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 7% to $12.3 million, driven primarily by a new corporate collaboration with SmithKlineBeecham (GSK), partially offset by the conclusion of the Pharmacia Corporation relationship in 2002.
• Expense Increases: Research and Development (R&D) expenses rose 16% to $30.3 million. This was due to increased personnel costs (6% increase), lab supplies (4% increase), and a 146% surge in license and consulting fees related to advancing clinical programs (specifically XL784 and the rebeccamycin analogue).
• Net Loss Expansion: Net loss widened by approximately $4.6 million year-over-year, reflecting the significant increase in R&D spending outpacing revenue growth.
• Cash Flow Improvement: Net cash used in operating activities decreased significantly to $15.4 million from $26.3 million in the prior year, aided by an increase in deferred revenue from collaborators.

Guidance, Outlook, and Risks

• Clinical Milestones: The company submitted its first Investigational New Drug (IND) application for its proprietary small molecule anticancer compound, XL784, in Q1 2003. Phase 1 studies in healthy volunteers are planned for Q2 2003 pending FDA clearance.
• Rebeccamycin Analogue: The Phase 2 clinical testing program for the rebeccamycin analogue (XL119), conducted by the National Cancer Institute, is well advanced. The company anticipates initiating next development steps following FDA discussions.
• Profitability Outlook: Exelixis expects to incur additional operating losses for the foreseeable future as it advances drug discovery and development programs. Profitability is not expected until significant additional revenues are generated.
• Capital Needs: While current cash is sufficient for two years, the company may seek additional financing through public/private offerings or collaborations. Future equity financing may be dilutive.
• Key Risks:
  • Dependence on collaborations for revenue; failure to meet milestones or renew agreements could reduce revenue.
  • Regulatory uncertainty and the lengthy process for FDA approval.
  • Reliance on third-party manufacturers for clinical trial materials.
  • High competition and potential obsolescence of technology.

Investor Verification Checklist

• IND Approval Status: Verify the FDA's acceptance of the XL784 IND application and the actual start date of Phase 1 trials.
• Collaboration Renewals: Monitor the status of expiring agreements, specifically with Protein Design Labs (June 2003) and Dow AgroSciences (July 2003).
• Cash Burn Rate: Track quarterly operating cash flow to ensure the "two-year runway" estimate remains valid given rising R&D costs.
• Rebeccamycin Phase 2 Results: Review upcoming data from the National Cancer Institute trials for the rebeccamycin analogue.
• Stock Option Dilution: Note the significant number of options granted to employees and officers (976,236 net shares in Q1) and their potential dilutive impact.